{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:47:41Z","timestamp":1771919261789,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00432-021-03716-1","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T14:02:52Z","timestamp":1627048972000},"page":"1195-1210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals"],"prefix":"10.1007","volume":"148","author":[{"given":"Rixiong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binbin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8781-109X","authenticated-orcid":false,"given":"Qing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"3716_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","volume":"106","author":"SJ Bagley","year":"2017","unstructured":"Bagley SJ, Kothari S, Aggarwal C et al (2017) Pretreatment neutrophilto-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106:1\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2017.01.013","journal-title":"Lung Cancer"},{"issue":"7","key":"3716_CR2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMc2021840","volume":"383","author":"D Bomze","year":"2020","unstructured":"Bomze D, Meirson T, Azoulay D (2020) Atezolizumab and bevacizumab in hepatocellular carcinoma. N Engl J Med 383(7):693\u2013694. https:\/\/doi.org\/10.1056\/NEJMc2021840","journal-title":"N Engl J Med"},{"issue":"6","key":"3716_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"issue":"10064","key":"3716_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389(10064):56\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(16)32453-9","journal-title":"Lancet"},{"issue":"6","key":"3716_CR5","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.pan.2016.09.007","volume":"16","author":"H Cheng","year":"2016","unstructured":"Cheng H, Luo G, Lu Y et al (2016) The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Pancreatology 16(6):1080\u20131084. https:\/\/doi.org\/10.1016\/j.pan.2016.09.007","journal-title":"Pancreatology"},{"issue":"2","key":"3716_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","volume":"72","author":"AL Cheng","year":"2020","unstructured":"Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M (2020) Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol 72(2):307\u2013319. https:\/\/doi.org\/10.1016\/j.jhep.2019.09.025","journal-title":"J Hepatol"},{"issue":"20","key":"3716_CR7","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.3748\/wjg.v25.i20.2416","volume":"25","author":"C Choi","year":"2019","unstructured":"Choi C, Yoo GS, Cho WK, Park HC (2019) Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J Gastroenterol 25(20):2416\u20132429. https:\/\/doi.org\/10.3748\/wjg.v25.i20.2416","journal-title":"World J Gastroenterol"},{"issue":"10088","key":"3716_CR8","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389(10088):2492\u20132502. https:\/\/doi.org\/10.1016\/S0140-6736(17)31046-2","journal-title":"Lancet"},{"key":"3716_CR9","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1053\/j.gastro.2008.02.090","volume":"134","author":"HB El-Serag","year":"2008","unstructured":"El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134:1752\u20131763. https:\/\/doi.org\/10.1053\/j.gastro.2008.02.090","journal-title":"Gastroenterology"},{"issue":"20","key":"3716_CR10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894\u20131905. https:\/\/doi.org\/10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"issue":"5","key":"3716_CR11","first-page":"1016","volume":"7","author":"YA Fouad","year":"2017","unstructured":"Fouad YA, Aanei C (2017) Revisiting the hallmarks of cancer. Am J Cancer Res 7(5):1016\u20131036","journal-title":"Am J Cancer Res"},{"issue":"18","key":"3716_CR12","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.2169\/internalmedicine.3726-19","volume":"59","author":"R Fukuda","year":"2020","unstructured":"Fukuda R, Sugawara S, Kondo Y (2020) Immune checkpoint inhibitor can reduce HCV-RNA without liver damage. Intern Med 59(18):2245\u20132248. https:\/\/doi.org\/10.2169\/internalmedicine.3726-19","journal-title":"Intern Med"},{"issue":"4","key":"3716_CR13","first-page":"779","volume":"2","author":"J Furuse","year":"2008","unstructured":"Furuse J (2008) Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biologics 2(4):779\u2013788","journal-title":"Biologics"},{"issue":"12","key":"3716_CR14","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17(12):e542\u2013e551. https:\/\/doi.org\/10.1016\/S1470-2045(16)30406-5","journal-title":"Lancet Oncol"},{"issue":"4","key":"3716_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.4254\/wjh.v7.i4.673","volume":"7","author":"AI Gomaa","year":"2015","unstructured":"Gomaa AI, Waked I (2015) Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol 7(4):673\u2013687. https:\/\/doi.org\/10.4254\/wjh.v7.i4.673","journal-title":"World J Hepatol"},{"issue":"15 Suppl","key":"3716_CR16","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/jco.2013.31.15_suppl.3063","volume":"31","author":"K Gonda","year":"2013","unstructured":"Gonda K, Shibata M, Kanke Y, Yazawa T, Takenoshita S (2013) Circulating myeloid-derived suppressor cells (MDSC) and correlation to poor prognosis, Th2- polarization, inflammation, and nutritional damages in patients with gastric cancer. J Clin Oncol 31(15 Suppl):3063","journal-title":"J Clin Oncol"},{"key":"3716_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/01.wad.0000201851.52707.c9","volume":"20","author":"L Jonsson","year":"2006","unstructured":"Jonsson L, Andreasen N, Kilander L et al (2006) Patient-and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord 20:49\u201355. https:\/\/doi.org\/10.1097\/01.wad.0000201851.52707.c9","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"10126","key":"3716_CR18","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163\u20131173. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1","journal-title":"Lancet"},{"issue":"5","key":"3716_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000505933","volume":"43","author":"HY Kuo","year":"2020","unstructured":"Kuo HY, Chiang NJ, Chuang CH et al (2020) Impact of immune checkpoint inhibitors with or without a combination of tyrosine kinase inhibitors on organ-specific efficacy and macrovascular invasion in advanced hepatocellular carcinoma. Oncol Res Treat 43(5):211\u2013220. https:\/\/doi.org\/10.1159\/000505933","journal-title":"Oncol Res Treat"},{"issue":"6","key":"3716_CR20","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","volume":"21","author":"MS Lee","year":"2020","unstructured":"Lee MS, Ryoo BY, Hsu CH et al (2020) Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol 21(6):808\u2013820. https:\/\/doi.org\/10.1016\/S1470-2045(20)30156-X","journal-title":"Lancet Oncol"},{"issue":"4","key":"3716_CR21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Vlierberghe HV (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390. https:\/\/doi.org\/10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"issue":"10","key":"3716_CR22","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","volume":"15","author":"JM Llovet","year":"2018","unstructured":"Llovet JM, Montal R, Sia D, Finn RS (2018) Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 15(10):599\u2013616. https:\/\/doi.org\/10.1038\/s41571-018-0073-4","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"3716_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.smim.2016.03.018","volume":"28","author":"K Moses","year":"2016","unstructured":"Moses K, Brandau S (2016) Human neutrophils: their role in cancer and relation to myeloid-derived suppressor cells. Semin Immunol 28(2):187\u2013196. https:\/\/doi.org\/10.1016\/j.smim.2016.03.018","journal-title":"Semin Immunol"},{"issue":"1","key":"3716_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4161\/onci.1.1.18344","volume":"1","author":"AD Pardee","year":"2012","unstructured":"Pardee AD, Butterfield LH (2012) Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities. Oncoimmunology 1(1):48\u201355. https:\/\/doi.org\/10.4161\/onci.1.1.18344","journal-title":"Oncoimmunology"},{"key":"3716_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102031","volume":"87","author":"G Pasello","year":"2020","unstructured":"Pasello G, Pavan A, Attili I et al (2020) Real world data in the era of immune checkpoint inhibitors (ICIs): increasing evidence and future applications in lung cancer. Cancer Treat Rev 87:102031. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102031","journal-title":"Cancer Treat Rev"},{"key":"3716_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fonc.2019.00052","volume":"9","author":"J Reul","year":"2019","unstructured":"Reul J, Frisch J, Engeland CE et al (2019) Tumor-specific delivery of immune checkpoint inhibitors by engineered AAV vectors. Front Oncol 9:52. https:\/\/doi.org\/10.3389\/fonc.2019.00052","journal-title":"Front Oncol"},{"issue":"7","key":"3716_CR27","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2217\/fon-2020-0986","volume":"17","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Ricci AD, Brandi G (2021a) Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. Future Oncol 17(7):755\u2013757. https:\/\/doi.org\/10.2217\/fon-2020-0986","journal-title":"Future Oncol"},{"issue":"8","key":"3716_CR28","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2217\/imt-2021-0026","volume":"13","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Ricci AD, Brandi G (2021b) Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy 13(8):637\u2013644. https:\/\/doi.org\/10.2217\/imt-2021-0026","journal-title":"Immunotherapy"},{"key":"3716_CR29","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2147\/OTT.S153290","volume":"11","author":"DB Sacdalan","year":"2018","unstructured":"Sacdalan DB, Lucero JA, Sacdalan DL (2018) Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther 11:955\u2013965. https:\/\/doi.org\/10.2147\/OTT.S153290","journal-title":"Onco Targets Ther"},{"issue":"4","key":"3716_CR30","doi-asserted-by":"publisher","first-page":"463","DOI":"10.4103\/0973-1482.92023","volume":"7","author":"M Salhab","year":"2011","unstructured":"Salhab M, Canelo R (2011) An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther 7(4):463\u2013475. https:\/\/doi.org\/10.4103\/0973-1482.92023","journal-title":"J Cancer Res Ther"},{"issue":"10105","key":"3716_CR31","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390(10105):1853\u20131862. https:\/\/doi.org\/10.1016\/S0140-6736(17)31601-X","journal-title":"Lancet"},{"issue":"11","key":"3716_CR32","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1111\/liv.14210","volume":"39","author":"YY Shao","year":"2019","unstructured":"Shao YY, Liu TH, Hsu C et al (2019) Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver Int 39(11):2184\u20132189. https:\/\/doi.org\/10.1111\/liv.14210","journal-title":"Liver Int"},{"key":"3716_CR33","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/hep.30889","volume":"71","author":"K Shigeta","year":"2019","unstructured":"Shigeta K, Datta M, Hato T et al (2019) Duan programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology 71:1247\u20131261. https:\/\/doi.org\/10.1002\/hep.30889","journal-title":"Hepatology"},{"key":"3716_CR34","doi-asserted-by":"publisher","first-page":"175883592090909","DOI":"10.1177\/1758835920909091","volume":"12","author":"CE Simmons","year":"2020","unstructured":"Simmons CE, Brezden-Masley C, McCarthy J, McLeod D, Joy AA (2020) Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer. Ther Adv Med Oncol 12:1758835920909091. https:\/\/doi.org\/10.1177\/1758835920909091","journal-title":"Ther Adv Med Oncol"},{"key":"3716_CR35","doi-asserted-by":"publisher","first-page":"10335","DOI":"10.2147\/OTT.S214870","volume":"12","author":"SH Tella","year":"2019","unstructured":"Tella SH, Mahipal A, Kommalapati A, Jin Z (2019) Evaluating the safety and efficacy of nivolumab in patients with advanced hepatocellular carcinoma: evidence to date. Onco Targets Ther 12:10335\u201310342. https:\/\/doi.org\/10.2147\/OTT.S214870","journal-title":"Onco Targets Ther"},{"issue":"4","key":"3716_CR36","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3390\/vaccines8040578","volume":"8","author":"F Tovoli","year":"2020","unstructured":"Tovoli F, De Lorenzo S, Trevisani F (2020) Immunotherapy with checkpoint inhibitors for hepatocellular carcinoma: where are we now? Vaccines (basel) 8(4):578. https:\/\/doi.org\/10.3390\/vaccines8040578","journal-title":"Vaccines (basel)"},{"key":"3716_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31187","author":"A Vitale","year":"2020","unstructured":"Vitale A, Trevisani F, Farinati F, Cillo U (2020) Treatment of hepatocellular carcinoma in the precision medicine era: from treatment stage migration to therapeutic hierarchy. Hepatology. https:\/\/doi.org\/10.1002\/hep.31187","journal-title":"Hepatology"},{"key":"3716_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110797","volume":"132","author":"Y Wang","year":"2020","unstructured":"Wang Y, Jiang M, Zhu J et al (2020) The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. Biomed Pharmacother 132:110797. https:\/\/doi.org\/10.1016\/j.biopha.2020.110797","journal-title":"Biomed Pharmacother"},{"key":"3716_CR39","doi-asserted-by":"publisher","first-page":"175883591986269","DOI":"10.1177\/1758835919862692","volume":"11","author":"W Xu","year":"2019","unstructured":"Xu W, Liu K, Chen M et al (2019) Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. Ther Adv Med Oncol 11:1758835919862692. https:\/\/doi.org\/10.1177\/1758835919862692","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"3716_CR40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau T, Kang YK, Kim TY et al (2020) Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol 6(11):e204564. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4564","journal-title":"JAMA Oncol"},{"issue":"4","key":"3716_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3892\/ol.2020.11909","volume":"20","author":"Z Zeng","year":"2020","unstructured":"Zeng Z, Yang B, Liao ZY (2020) Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma. Oncol Lett 20(4):45. https:\/\/doi.org\/10.3892\/ol.2020.11909","journal-title":"Oncol Lett"},{"issue":"7","key":"3716_CR42","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J et al (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19(7):940\u2013952. https:\/\/doi.org\/10.1016\/S1470-2045(18)30351-6","journal-title":"Lancet Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03716-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03716-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03716-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T07:29:59Z","timestamp":1650353399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03716-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3716"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03716-1","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"28 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}